Pharma Business - April 17, 2015
Novo Opens Russian Facility
Novo Nordisk has opened a new manufacturing facility in the Kaluga region of Russia for the production of modern devices for administering insulin for treating diabetes. The facility will produce both Penfill® cartridges and FlexPen® prefilled insulin injection pens for the Russian market, according to FiercePharma. The new facility is located in Technopark Grabtsevo and […]
Companies - April 15, 2015
Novo Extends Diabetes Aid
Novo Nordisk has extended its Changing Diabetes® in Children program for another three years, according to a company announcement. Since 2009, the company has provided free insulin and access to diabetes care to more than 13,000 children in nine countries in Africa and Southeast Asia. In addition, 108 diabetes clinics have been established and 5,479 healthcare […]
Drug Development Pharma - April 9, 2015
FDA Accepts Novo Resubmission
The US Food and Drug Administration (FDA) has accepted for review Novo Nordisk’s Class II Resubmissions for Tresiba® (insulin degludec) and Ryzodeg® (insulin degludec/insulin aspart). To preserve the integrity of the ongoing DEVOTE trial, only a small team within Novo Nordisk has access to the data, according to the company. This team has prepared the interim analysis […]
Companies - April 2, 2015
Support for Hemophilia Patients
Novo Nordisk has launched a comprehensive patient support program, NovoSecure, for people with hemophilia. Eligible patients can apply for assistance including career counseling and HeroPath life coaching, which are specifically tailored to help patients address the often overlooked aspects of living with a chronic disease. NovoSecure was created as a result of information obtained through […]
Clinical Trials - March 27, 2015
Novo to Resubmit Drugs to FDA
Novo Nordisk has decided to resubmit the prespecified interim analysis of DEVOTE as part of a Class II Resubmission of the New Drug Applications (NDAs) of Tresiba® and Ryzodeg® to the US Food and Drug Administration (FDA). The resubmission is expected to take place within the next month, according to the company. The cardiovascular outcomes trial for […]
Acquisition - March 25, 2015
Novo Sells Autoimmune Program
Novo Nordisk has sold one of its early-stage autoimmune research programs to Bristol-Myers Squibb for an undisclosed amount. As part of the agreement, Bristol-Myers obtains the exclusive rights to a discovery-stage biologics program that targets the innate immune system, which is the body’s first line of defense against infection. Novo’s program was striving to treat […]
